Critical appraisal of scientific posters comparing anemia treatments for cancer patients: Applying ispor task force guidelines on methodological quality of retrospective studies

Critical Reviews in Oncology/Hematology

Volumn 63, Issue 2, 2007, Pages 91-99

  Demarteau, Nadia ^a   Moeremans, Karen ^a   Annemans, Lieven ^a,b  

^a IQVIA   (United States)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Database; Epoetin; Guidelines; Methodology; Poster

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BELGIUM; CANCER; CANCER RESEARCH; CLINICAL RESEARCH; COST OF ILLNESS; DISEASE ASSOCIATION; DRUG COST; FRANCE; HUMAN; INTERMETHOD COMPARISON; METHODOLOGY; PRACTICE GUIDELINE; REVIEW; SCORING SYSTEM; SENSITIVITY ANALYSIS;

ANEMIA; ANTINEOPLASTIC AGENTS; BENCHMARKING; DATA INTERPRETATION, STATISTICAL; EPOETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; GUIDELINES; HEMATINICS; HUMANS; NEOPLASMS; RESEARCH DESIGN; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 34250829258     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2007.02.005     Document Type: Review

References (16)

1. Hammarling S., and Higham N.J. How to prepare a poster?. Society for Industrial and Applied Mathematics News 29 4 (1996) 1-3
2. Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services. The National Guideline Clearinghouse™ (NGC) 1998-2005. Available at http://www.guideline.gov. Last accessed August 2005.
3. Shiffman R.N., Dixon J., Brandt C., et al. The GuideLine Implementability Appraisal (GLIA): development of an instrument to identify obstacles to guideline implementation. BMC Med Inform Decis Mak 5 (2005) 23
4. Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., and Russell L.B. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276 (1996) 1253-1258
5. Drummond M.F., and Jefferson T.O. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 313 (1996) 275-283
6. Motheral B., Brooks J., Clark M.A., et al. A checklist for retrospective database studies-report of the ISPOR Task Force on retrospective databases. Value Health 6 2 (2003) 90-97
7. Marchetti M., and Barosi G. Clinical and economic impact of epoetins in cancer care. Pharmacoeconomics 22 16 (2004) 1029-1045
8. Stasi R., Amadori S., Littlewood T.J., Terzoli E., Newland A.C., and Provan D. Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns. Oncologist 10 7 (2005) 539-554
9. Persson U., Borg S., Jansson S., et al. Differences in treatment practice, response rates and cost of epoetin alfa and darbepoetin alfa treatment for anemic cancer patients: a retrospective analysis from Sweden. Value Health 7 6 (2004) 681
10. Reichardt B. Evidence-based, novel comparison between Epoetin alfa, epoetin beta, and darbepoetin alfa based on drug use, efficacy and treatment costs in daily oncological clinical practice (June 2004), European Hematology Association, Geneva (Abstract 513)
11. Reichardt B. Versorgungsvereich rHu-Epoetin und Darbepoetin in der Tumoranämie. Österreichische Gesellschaft für Hämatologie und Onkologie (April 2004)
12. Malonne H. Cost evaluation of erythropoesis stimulating agents in the treatment of platinum chemotherapy-induced anaemia (2005), Belgian Hematology Society, Genval
13. Pujade-Lauraine E., Richard A.J., and Sapède C. Erythropoietic agents in routine clinical practice: a retrospective observational survey of epoetin alfa, epoetin beta and darbepoetin alfa use in anaemic patients with cancer (2004), European Society of Medical Oncology, Vienna (Abstract 835)
14. Littlewood T.J., Schenkel B., and Liss M. Effect of patient exclusion criterion on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia. Oncologist 10 5 (2005) 357-360
15. Pujade-Lauraine E., Richard A.J., Sapede C., and Hayward C. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice. Oncol Rep 14 4 (2005) 1037-1044
16. Persson U., Borg S., Jansson S., et al. Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: comparative analysis of drug utilization, costs, and hematologic response. Adv Ther 22 3 (2005) 208-224